Evofem Biosciences, Inc.
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women`s sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). Evofem Biosciences exists to advance the lives of women. We believe this work centers around putting each woman in control of her sexual and reproductive health. By providing innovative solutions, such as woman-controlled contraception and protection from sexually transmitted infections (STIs), we can move swiftly toward our goal of upholding the purpose each woman chooses for her life.
We will discover and develop innovative healthcare solutions that put women first.
We will give women everywhere control of their sexual and reproductive health.
Protecting her life’s purpose is our purpose.
Women never stop evolving, and neither will we.
Evofem Biosciences is passionately committed to addressing the changing needs of women everywhere. Through smart partnerships,
we will bring products to those who need them faster and serve markets that are difficult to reach with traditional distribution channels, thereby effectively responding to the critical sexual and reproductive health concerns of millions of women.
The Company’s first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
The Company is evaluating its investigational drug candidate EVO100 vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. In October 2020, Evofem initiated EVOGUARD, a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of EVO100 for the prevention of chlamydia and gonorrhea infection in women. Top-line results are expected in 2022.
EVOGUARD builds on reported positive, statistically significant top-line data from a double-blind placebo-controlled Phase 2b clinical trial (AMPREVENCE). This landmark study met its primary and secondary endpoints, demonstrating a 50% relative risk reduction in chlamydia infection and a 78% relative risk reduction in gonorrhea infection compared to placebo. AMPREVENCE results were presented at the 2020 STD Prevention Virtual Conference (view poster).
The Company has assembled a very strong management team with significant operational experience in the biopharmaceutical market. Specifically, our senior executives have a successful track record of developing and commercializing women’s health products including Mirena, Plan B One-Step, Yasmin, YAZ, NuvaRing, Paragard and Seasonique, among others.